Good day,
Thank you for subscribing to the Earnings360 newsletter, your daily source for quarterly earnings news and updates.
Each morning edition contains a wrap-up of today's pre-market earnings announcements and yesterday's earnings announcements after the closing bell.
Before we send you your first edition, please take a moment to confirm your subscription below. We will not be able to send your newsletter until you confirm your subscription.
Confirm Your Subscription Here
The Earnings360 Team
Further Reading from MarketBeat Media Why Wall Street Is Backing These 3 Comeback StocksWritten by Nathan Reiff. Published 10/28/2025. 
Key Points - Stocks staging a comeback rally can reward investors willing to take a risk with significant gains.
- Analysts have flagged companies including The Trade Desk, Summit Therapeutics, and Sprouts Farmers Market as having sizable upside potential after earlier declines.
- These companies face external challenges of various kinds, but offer compelling product lineups or pipelines and fundamentals.
A company's comeback story can mean a significant opportunity for investors. When a stock has lost a sizable portion of its value recently, many investors prefer to be cautious unless there are clear signs the firm's fortunes could turn. If a rally does materialize, however, shareholders who bought during the dip may see the largest gains. Wall Street analysts have identified three companies below—The Trade Desk Inc. (NASDAQ: TTD), Summit Therapeutics PLC (NASDAQ: SMMT), and Sprouts Farmers Market Inc. (NASDAQ: SFM)—each from a different industry and sector, that could be poised for a comeback. Shares of all three have fallen over the past several months, but each presents a potentially compelling opportunity for investors willing to accept a fair degree of risk. External Threats Impact The Trade Desk, But Platform Relaunch Could Boost Interest Just like Microsoft and Adobe rode the software wave in Web 1.0, RAD Intel is riding the AI software wave in 2025. Their product helps brands instantly find the right audience and message using AI – solving the #1 waste in marketing: misfired ad spend.
Already trusted by a who's-who of Fortune 1000 brands and leading global agencies – with recurring seven-figure partnerships in place. With a Nasdaq ticker reserved, $RADI, it's early – but very real. $0.81 won't last – deadline Nov 20 Ad tech firm The Trade Desk is down more than 54% year-to-date after missing its latest EPS estimate by $0.24. The company faces mounting competition from tech rivals not primarily focused on advertising, including Amazon.com Inc. (NASDAQ: AMZN), which recently offered potential advertising customers free use of its demand-side platform (DSP) to test against competitors' products. That move directly threatens TTD, especially after the firm lost its exclusive partnership with Walmart Inc. (NYSE: WMT) over the summer. There are reasons for optimism, though. Despite a slowdown, TTD's revenue grew 19% year-over-year for the latest quarter, and it remains one of the leading ad tech platforms. Some of the slowdown stems from user pushback on its Kokai platform, but in September the company announced a range of enhancements that could renew interest. One notable addition, Deal Desk—launched earlier this year—addresses an important gap as a deal optimization and pacing tool. Analysts are somewhat mixed on TTD, but a majority (21 of 37) rate the stock a Buy. TTD has a consensus price target of more than $84, roughly 58% above its current trading level. Summit's Pipeline Is Promising, But Cash Position Is a Risk Clinical-stage biotech firm Summit Therapeutics is best known for ridinilazole, a candidate for treating Clostridioides difficile infections. The company is not yet profitable and reported wider-than-expected losses per share in its third quarter of 2025. Summit's largest near-term challenge may be its cash runway: it ended the latest quarter with less than $239 million in cash and rising operating expenses that are depleting reserves quickly. Executives have suggested a potential equity financing or at-the-market offering to fund ongoing trials. That would provide capital but dilute current shareholders, and SMMT shares have fallen nearly 20% over the last six months amid those prospects. Still, Summit's pipeline is promising if it can address cash-flow concerns. The company plans to submit a biologics license application for Ivonescimab, a potential lung cancer treatment, this quarter, and its phase III trial is set to expand—a positive sign for future marketability. Twelve of 18 analysts rate SMMT shares a Buy, and the company has upside potential of about 60% based on a consensus price target of $31.14. Strong Fundamentals Could Help Sprouts to Trend Higher Organic specialty grocer Sprouts Farmers Market has seen shares drop almost 20% this year amid inflation and weaker consumer sentiment. However, the company's latest earnings were solid: it posted top- and bottom-line beats, with sales up 17% year-over-year, led by strong e-commerce growth. Management subsequently raised its full-year outlook. Sprouts has also returned capital to shareholders, deploying operating cash flow of more than $400 million as of midyear, including $292 million for share repurchases. The company's focus on higher-income customers and affluent regions may help insulate it from rising grocery prices and tariff pressures. Analysts appear constructive: 10 of 15 rate SFM a Buy, and the stock shows about 51% upside potential.
| 
